| Novartis ends Tekturna trial on safety concerns - FiercePharma |
|
|
FiercePharma The drug company has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also at high risk of cardiovascular and renal events after researchers saw an increased number of adverse events--including ... Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in |